San Diego, CA, May 3, 2016 — After his participation in the Fourth National Debate for the Usage of Marijuana and his historic speech with Mexican President Peña Nieto, Raúl Elizalde, Founder of Por Grace (Por Todos), will hold a meeting with Dr. Stuart Titus, CEO of Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the U.S. Among the meeting discussion topics will be RSHO-X™, the first-ever cannabis product to receive approval from the federal government of Mexico for importation.
Dr. Titus states, “We are extremely impressed with Raul Elizalde’s passion for the health and wellbeing of others around the world. In his speech at the final National Debate on the Usage of Marijuana in Mexico City, he specifically differentiates between the psychoactive forms of cannabis as opposed to non-psychoactive forms – which includes industrial hemp-derived cannabidiol or ‘CBD’.
He noted to the audience that there is ‘much work to be done’ with changing laws about cannabis access in Mexico. However, that work has now received the blessing of Mexico’s President Nieto.”
The meeting with Dr. Titus and Elizalde will take place at Medical Marijuana, Inc. headquarters and will allow Elizalde to show the medical progress that his daughter, Grace Elizalde, has had after using (cannabidiol) CBD hemp oil for the treatment of seizures caused by Lennox Gastaut syndrome. Titus will update Elizalde on the work that Medical Marijuana, Inc. is doing in Latin America, and being the first company to receive approval from COFEPRIS (the Federal Commission for the Protection Against Sanitary Risks) to import RSHO-X™ into Mexico for families there.
“Medical Marijuana, Inc. was the first company to receive approval from COFEPRIS for our RSHO-X product, the first patients to receive it were Maria Paula and Alina Maldonado Montes de Oca, whose father Abelardo Maldonado Constantino rode eight hours – one way – by bus to pick up his import permit,” Dr. Titus said. “We applaud the government of Mexico, in particular COFEPRIS, as well as the great work of Raúl Elizalde with the Por Grace foundation for helping to open up access to hemp CBD products such as RSHO-X™ to the people of Mexico.”
The May 4th meeting allows Medical Marijuana, Inc. executives and Elizalde to collaborate on how to open up even greater access to the Company’s hemp CBD-based products to the people of Mexico, and also discuss how to better educate health professionals and patients about recent studies and the U.S. Department of Health and Human Services’ Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants”.
This alliance reinforces the commitment of Medical Marijuana, Inc. and its subsidiary company HempMeds® to promote the universal right to health for all residents in both the United States and Mexico, but also call for governments around the world to reform laws permitting access to cannabis.
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink: MJNA) and the Company’s exclusive master distributor and contracted marketing company.
About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
The Company is committed to consistently providing the highest-quality CBD hemp oil products on the market. To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp- based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact: Public Relations contact:
Corporate contact: Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
Investor Relations: Nicholas R. Massalas
Director of Business Development Medical Marijuana Inc.
OTC Symbol: MJNA
Toll Free: (877) 964.6463
Direct: (858) 264-6505